Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

Organon

Status and phase

Completed

Phase 3

Conditions

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

Treatments

Drug: Comparator : atenolol /Duration of Treatment : 5 Years

Drug: MK0954, /Duration of Treatment : 5 Years

Study type

Interventional

Funder types

Industry

Identifiers

NCT00338260

2006_502

0954-133

Details and patient eligibility

About

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Enrollment

496 patients

Sex

All

Ages

55 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 55 to 80 years
Males and females
Hypertension (160-200/95-115 mm Hg
ECG evidence of left ventricular hypertrophy

Exclusion criteria

Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
Myocardial infarction or stroke within 6 months